Diede, Scott J
Merck & Co., Inc., Rahway, NJ, USA (United States)
4 papers on CoChatORCID 0000-0001-5422-549X
Most cited papers
- Verified
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell
Cancer Immunotherapy and BiomarkersVirus-based gene therapy research
Cited by 1,520
- Verified
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A., Carlino, M. S., Grob, J.-J., Kim, T. M., et al. (2019) · The Lancet Oncology
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 960
- Verified
Telomerase-Mediated Telomere Addition In Vivo Requires DNA Primase and DNA Polymerases α and δ
Diede, S. J., & Gottschling, D. E. (1999) · Cell
Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model Organisms
Cited by 379
- Verified
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
Geoerger, B., Kang, H. J., Yalon-Oren, M., Marshall, L. V., Vezina, C., Pappo, A., Laetsch, T. W., Petrilli, A. S., Ebinger, M., Toporski, J., et al. (2020) · The Lancet Oncology
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 357
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free